OINDP research and development specialist Nanopharm has partnered with Leyden Labs for development of Leyden Labs antiviral nasal spray candidates, the companies have announced. Nanopharm, which was acquired by Aptar Pharma in 2019, will develop a liquid nasal formulation in preparation for Phase 1 trials and may evaluate a powder formulation as well. In March 2021, … [Read more...] about Leyden Labs partners with Nanopharm on antiviral nasal spray development
News
Meissa announces results of preclinical testing of its intranasal COVID-19 vaccine, Phase 1 trial update
Meissa Vaccines said that a SARS-CoV-2 challenge test of its MV-014-212 intranasal live attenuated vaccine candidate in non-human primates demonstrated similar efficacy for a single dose compared to currently available vaccines, and the intranasal vaccine stimulated both mucosal and systemic antibodies. According to the company, the vaccine generated antibodies able … [Read more...] about Meissa announces results of preclinical testing of its intranasal COVID-19 vaccine, Phase 1 trial update
Iconovo to provide dry powder nasal device for ISR intranasal COVID-19 vaccine
Device developer Iconovo has received an order worth up to 4.9 million Swedish kronor from Immune System Regulation (ISR) for an intranasal version of Iconovo's ICOone single dose DPI, the company said. In March 2021, Iconovo announced that it had received an order from ISR for development of the ICOone device for a COVID-19 vaccine. The addition of the nasal version … [Read more...] about Iconovo to provide dry powder nasal device for ISR intranasal COVID-19 vaccine
Philip Morris announces £1 billion offer for Vectura
Philip Morris International (PMI) has announced an offer of ~£1.05 billion for the acquisition of inhalation CDMO Vectura. In May 2021, Vectura announced that it would be acquired by the Carlyle Group for £958 million. The Vectura Board has withdrawn its support for the Carlyle deal and agreed to the PMI acquisition, citing PMI's experience with aerosol delivery among … [Read more...] about Philip Morris announces £1 billion offer for Vectura
AIM ImmunoTech announces planned human challenge trial of intranasal Ampligen against rhinovirus and flu
AIM ImmunoTech has announced a planned Phase 2a human challenge trial of intranasal Ampligen rintatolimod against human rhinovirus and influenza. The company suggested that "Success against these common viruses could also indicate that an Ampligen prophylaxis could help blunt the spread of infection from lethal coronaviruses, as well as other serious viruses." The … [Read more...] about AIM ImmunoTech announces planned human challenge trial of intranasal Ampligen against rhinovirus and flu
Opiant announces positive results from PK study of OPNT003 intranasal nalmefene
Opiant Pharmaceuticals said that a PK study of its OPNT003 intranasal nalmefene, which it is developing for opioid overdose, demonstrated that the Tmax of the nasal formulation was about 15 minutes, similar to that shown in a previous pilot study, and Cmax was slightly higher than for an intramuscular injection of nalmefene and higher than in the pilot study. The … [Read more...] about Opiant announces positive results from PK study of OPNT003 intranasal nalmefene
Washington Research Foundation awards grant for development of inhaled miniprotein for IPF
Anindya Roy, a researcher at the University of Washington Institute for Protein Design (IPD), has received a $250,000 grant from Washington Research Foundation (WRF) for continued development of an inhaled miniprotein binder for the treatment of idiopathic pulmonary fibrosis (IPF), WRF has announced. According to WRF, Roy's miniprotein binds to the αvβ6 integrin, … [Read more...] about Washington Research Foundation awards grant for development of inhaled miniprotein for IPF
Rokote Labs gets €9 million for development of intranasal COVID vaccine
Rokote Laboratories, a spin out from the University of Helsinki and the University of Eastern Finland, has raised €9 million for development of an intranasal vaccine against the SARS-CoV-2 virus, the universities have announced. The funding, which includes €3.5 million from the Finnish Cultural Foundation, Ferring Ventures SA, and the Jenny and Antti Wihuri … [Read more...] about Rokote Labs gets €9 million for development of intranasal COVID vaccine
Atossa announces Phase 1/2a study of nebulized AT-H201
Atossa Therapeutics said that the Human Research Ethics Committee (HREC) of the Australian National Health and Medical Research Council (NHMRC) has okayed a Phase 1/2a clinical study of the company's nebulized AT-H201, which is "is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes." The … [Read more...] about Atossa announces Phase 1/2a study of nebulized AT-H201
PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI
Dutch DPI developer Pure IMS has announced a new partnership with CDMO Sever Pharma Solutions (formerly Disphar International) and Radboud University Medical Center (Radboudumc) for development of a tigecycline dry powder inhaler for the treatment of multi-drug resistant Mycobacterium abscessus lung infections. Radboudumc research has demonstrated that inhaled … [Read more...] about PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI